Catawba Capital Management VA Trims Position in Zimmer Biomet Holdings Inc (ZBH)

Catawba Capital Management VA lowered its stake in shares of Zimmer Biomet Holdings Inc (NYSE:ZBH) by 3.3% in the 4th quarter, according to the company in its most recent disclosure with the SEC. The firm owned 42,119 shares of the medical equipment provider’s stock after selling 1,418 shares during the quarter. Zimmer Biomet makes up approximately 1.1% of Catawba Capital Management VA’s portfolio, making the stock its 28th largest holding. Catawba Capital Management VA’s holdings in Zimmer Biomet were worth $5,082,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently bought and sold shares of ZBH. Bank of Nova Scotia Trust Co. bought a new position in Zimmer Biomet during the third quarter worth about $112,000. FNY Managed Accounts LLC bought a new position in Zimmer Biomet during the third quarter worth about $117,000. BB&T Investment Services Inc. bought a new position in Zimmer Biomet during the second quarter worth about $144,000. Steward Partners Investment Advisory LLC bought a new position in Zimmer Biomet during the third quarter worth about $140,000. Finally, Stonebridge Capital Advisors LLC bought a new position in Zimmer Biomet during the second quarter worth about $202,000. Institutional investors own 86.06% of the company’s stock.

ZBH has been the subject of a number of research reports. Deutsche Bank upgraded shares of Zimmer Biomet from a “hold” rating to a “buy” rating and set a $128.00 target price for the company in a research report on Tuesday, November 14th. Edward Jones upgraded shares of Zimmer Biomet from a “hold” rating to a “buy” rating in a research report on Thursday, November 9th. SunTrust Banks set a $136.00 target price on shares of Zimmer Biomet and gave the stock a “buy” rating in a research report on Wednesday, November 1st. Jefferies Group reiterated a “buy” rating and set a $136.00 target price on shares of Zimmer Biomet in a research report on Friday, November 3rd. Finally, BMO Capital Markets reiterated a “buy” rating and set a $142.00 target price on shares of Zimmer Biomet in a research report on Tuesday, December 12th. Two equities research analysts have rated the stock with a sell rating, five have given a hold rating, sixteen have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Zimmer Biomet currently has a consensus rating of “Buy” and an average target price of $137.42.

Shares of Zimmer Biomet Holdings Inc (NYSE:ZBH) traded down $0.30 during trading on Friday, hitting $122.19. 1,077,700 shares of the stock were exchanged, compared to its average volume of 1,366,508. The stock has a market capitalization of $24,950.00, a P/E ratio of 38.07, a price-to-earnings-growth ratio of 1.91 and a beta of 1.15. The company has a debt-to-equity ratio of 0.88, a quick ratio of 0.78 and a current ratio of 1.47. Zimmer Biomet Holdings Inc has a 52-week low of $108.03 and a 52-week high of $133.49.

Zimmer Biomet (NYSE:ZBH) last announced its earnings results on Wednesday, November 1st. The medical equipment provider reported $1.72 earnings per share for the quarter, missing analysts’ consensus estimates of $1.74 by ($0.02). The company had revenue of $1.82 billion during the quarter, compared to analysts’ expectations of $1.83 billion. Zimmer Biomet had a net margin of 8.36% and a return on equity of 16.29%. The company’s revenue for the quarter was down .8% compared to the same quarter last year. During the same period in the prior year, the business earned $1.79 earnings per share. equities research analysts expect that Zimmer Biomet Holdings Inc will post 8.03 EPS for the current year.

The business also recently announced a quarterly dividend, which will be paid on Monday, January 29th. Investors of record on Friday, December 29th will be paid a $0.24 dividend. This represents a $0.96 dividend on an annualized basis and a yield of 0.79%. The ex-dividend date of this dividend is Thursday, December 28th. Zimmer Biomet’s dividend payout ratio is currently 29.91%.

TRADEMARK VIOLATION WARNING: This piece of content was first published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this piece of content on another site, it was stolen and reposted in violation of US and international copyright law. The original version of this piece of content can be viewed at https://www.dispatchtribunal.com/2018/01/19/catawba-capital-management-va-trims-position-in-zimmer-biomet-holdings-inc-zbh.html.

Zimmer Biomet Profile

Zimmer Biomet Holdings, Inc is engaged in designing, manufacturing and marketing of orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; office-based technologies; spine, craniomaxillofacial and thoracic products; dental implants, and related surgical products.

Institutional Ownership by Quarter for Zimmer Biomet (NYSE:ZBH)

Receive News & Ratings for Zimmer Biomet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply